These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 682250)

  • 41. Irritable colon syndrome treated with an antispasmodic drug.
    Practitioner; 1976 Aug; 217(1298):276-80. PubMed ID: 787960
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nicergoline in the treatment of neuropathic bladder dysfunction: a preliminary report.
    Gallego J; Forner V; Jimenez F; Martinez E
    Paraplegia; 1984 Aug; 22(4):216-24. PubMed ID: 6483464
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Effect of anticholinergics on bladder tonus and on the voiding function].
    Kelly LU; Wehnert J
    Z Urol Nephrol; 1979 Oct; 72(10):765-9. PubMed ID: 532394
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury.
    O'Leary M; Erickson JR; Smith CP; McDermott C; Horton J; Chancellor MB
    J Spinal Cord Med; 2003; 26(2):159-62. PubMed ID: 12828295
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride.
    Madersbacher H; Jilg G
    Paraplegia; 1991 Feb; 29(2):84-90. PubMed ID: 2023781
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Clinical effects of oxybutynin hydrochloride on neurogenic bladder].
    Toma H; Nakamura R
    Hinyokika Kiyo; 1986 Jun; 32(6):907-11. PubMed ID: 3532726
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction.
    Franco I; Horowitz M; Grady R; Adams RC; de Jong TP; Lindert K; Albrecht D
    J Urol; 2005 Jan; 173(1):221-5. PubMed ID: 15592080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Trospium chloride (spasmex) in the treatment of lower urinary tract symptoms in patients with neurogenic hyperactive urinary bladder caused by vertebrogenic lesions].
    Mazo EB; Babanina GA
    Urologiia; 2007; (3):15-9. PubMed ID: 17722614
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Irritable bowel syndrome: an effective treatment.
    Cane EM
    J Clin Gastroenterol; 1981 Jun; 3(2):200-1. PubMed ID: 7016974
    [No Abstract]   [Full Text] [Related]  

  • 50. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis.
    Madhuvrata P; Singh M; Hasafa Z; Abdel-Fattah M
    Eur Urol; 2012 Nov; 62(5):816-30. PubMed ID: 22397851
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction.
    Akbar M; Abel R; Seyler TM; Bedke J; Haferkamp A; Gerner HJ; Möhring K
    BJU Int; 2007 Sep; 100(3):639-45. PubMed ID: 17532858
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Anticholinergic treatment in the therapy of primary enuresis. Effectiveness of oxybutynin chloride in a controlled clinical study of 58 patients].
    Marconi AM; Felici E; Roggia A; Torelli F
    Pediatr Med Chir; 1985; 7(4):573-6. PubMed ID: 3915547
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Long-term efficacy of anticholinergic and alpha-blockader drugs on the detrusor muscle in children with myelomeningocele].
    Bouchot O; Buzelin JM; Labat JJ
    J Urol (Paris); 1988; 94(2):83-6. PubMed ID: 2899123
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The mechanism of action of dicyclomine hydrochloride on rabbit detrusor muscle and vas deferens.
    Johns A; Tasker JJ; Johnson CE; Theman MA; Paton DM
    Arch Int Pharmacodyn Ther; 1976 Nov; 224(1):109-13. PubMed ID: 189711
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Propiverine compared to oxybutynin in neurogenic detrusor overactivity--results of a randomized, double-blind, multicenter clinical study.
    Stöhrer M; Mürtz G; Kramer G; Schnabel F; Arnold EP; Wyndaele JJ;
    Eur Urol; 2007 Jan; 51(1):235-42. PubMed ID: 16698176
    [TBL] [Abstract][Full Text] [Related]  

  • 56. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity.
    Reitz A; Stöhrer M; Kramer G; Del Popolo G; Chartier-Kastler E; Pannek J; Burgdörfer H; Göcking K; Madersbacher H; Schumacher S; Richter R; von Tobel J; Schurch B
    Eur Urol; 2004 Apr; 45(4):510-5. PubMed ID: 15041117
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Efficacy of repeat injections of botulinum A toxin to the detrusor in neurogenic bladder overactivity].
    Chenet A; Perrouin-Verbe B; Le Normand L; Labat JJ; Brunel P; Lefort M; Mathé JF
    Ann Readapt Med Phys; 2007 Nov; 50(8):651-60. PubMed ID: 17490775
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lioresal in the treatment of neurogenic bladder dysfunction.
    Kiesswetter H; Schober W
    Urol Int; 1975; 30(1):63-71. PubMed ID: 1118949
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Treatment with oxybutynin hydrochloride of urinary incontinence and hyperactive bladder conditions in children].
    Aubert D; Cencig P; Royer M
    Ann Pediatr (Paris); 1986 Sep; 33(7):629-34. PubMed ID: 3777773
    [No Abstract]   [Full Text] [Related]  

  • 60. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study.
    Schurch B; de Sèze M; Denys P; Chartier-Kastler E; Haab F; Everaert K; Plante P; Perrouin-Verbe B; Kumar C; Fraczek S; Brin MF;
    J Urol; 2005 Jul; 174(1):196-200. PubMed ID: 15947626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.